• MA_5: $25.77
• MA_10: $25.85
• MA_20: $25.85
• MA_60: $26.71
• Summary: The current price ($25.34) is trading below all key moving averages (5, 10, 20, and 60-day). The alignment shows a clear bearish trend structure: 60-day > 10-day ≈ 20-day > 5-day > Current Price. This indicates sustained selling pressure and a medium-term downtrend.

2. Exponential Moving Averages (Recent Price Sensitivity):

• EMA_5: $25.65
• EMA_10: $25.77
• EMA_20: $25.94
• Analysis: The price is also below all exponential moving averages. The EMA_5 is below the EMA_10 and EMA_20, confirming short-term bearish momentum. The gap between the current price and the EMAs suggests the downtrend is accelerating.

3. MACD (Momentum and Trend Change):

• MACD Line: -0.2446
• Signal Line: -0.2517
• MACD Histogram (MACDH): +0.0070
• Analysis: The MACD line remains deeply in negative territory, confirming the primary bearish trend. However, the histogram has turned positive (albeit a very small +0.007), which is a potential early sign of bullish momentum divergence. This suggests the rate of decline may be slowing, but it is not yet a confirmed reversal signal. A crossover of the MACD line above the signal line is needed for confirmation.

4. RSI (Relative Strength Index - Overbought/Oversold):

• RSI (14-period): 36.82
• RSI (6-period): 27.35
• Analysis: The 14-period RSI at 36.82 is approaching oversold territory (typically below 30). The more sensitive 6-period RSI at 27.35 is already in oversold conditions. This indicates that the recent sell-off may have been excessive and that the stock is primed for a potential technical bounce or consolidation. However, oversold conditions can persist in strong downtrends.

5. Bollinger Bands (Volatility and Price Boundaries):

• Upper Band: $26.53
• Middle Band (20-day MA): $25.85
• Lower Band: $25.16
• Analysis: The current closing price of $25.34 is trading very close to the lower Bollinger Band ($25.16). Trading at or below the lower band often signals an oversold condition and can precede a mean-reversion move back towards the middle band. The bands are also narrowing slightly (Bandwidth = Upper - Lower = $1.37), suggesting a period of reduced volatility which often precedes a significant breakout.

6. KDJ (Stochastic Oscillator - Short-Term Cycles):

• K Value: 31.67
• D Value: 46.99
• J Value: 1.03
• Analysis: The J value is extremely low at 1.03, which is a strong oversold signal. The K line (31.67) is below the D line (46.99), which is bearish. However, such an extreme low J value often precedes a short-term reversal as selling exhausts.

7. Other Key Indicators:

• ATR (Average True Range): $0.47. This indicates the average daily trading range. It provides a baseline for setting stop-loss levels.
• Williams %R: -88.89. This is deeply in oversold territory (below -80), reinforcing the RSI and KDJ readings.
• CCI (Commodity Channel Index): -115.81. A value below -100 is considered oversold, suggesting a potential rebound.
• ADX (Average Directional Index): 12.17. This is a very low value, indicating a weak trend strength. Despite the clear price decline, the trend’s directional force is not strong, which can sometimes lead to choppy, range-bound consolidation.

📉 Price Trend Analysis

1. Overall Trend Direction: The price action for Pfizer, Inc. (PFE) over the provided 60-day period shows a clear downtrend. The stock peaked around $28.64 in early April 2026 and has since declined to the $25.30s by early June. The series of lower highs and lower lows is the textbook definition of a bearish trend.

2. Recent Price Action (Last 5 Days):

• 2026-05-29: $26.18
• 2026-06-01: $25.63 (Significant Gap Down)
• 2026-06-02: $25.55
• 2026-06-03: $25.34 The price broke below the $26.00 psychological support level on June 1st and has continued to drift lower on above-average volume (35.5M and 31.2M shares), confirming the breakdown.

3. Support and Resistance Level Analysis:

• Immediate Resistance: The cluster of moving averages (MA_5, MA_10, MA_20) between $25.77 and $25.85 forms the first strong resistance zone. The next key resistance is the 60-day MA at $26.71.
• Key Resistance: The early April high near $28.60-$28.70 is the major resistance for any sustained recovery.
• Immediate Support: The lower Bollinger Band at $25.16 is the nearest technical support. A break below this could trigger further selling.
• Major Support: Looking at the historical low within the data, the $25.24-$25.27 area (tested on May 15th and 19th) has provided temporary support. A decisive break below this level could open the path towards the $24.50 area.

4. Volume Analysis: Volume has been inconsistent but shows spikes on down days (e.g., April 28th: 58M shares, May 5th: 56M shares, June 1st: 35.5M shares). The recent decline from $26.18 to $25.34 has occurred on elevated volume compared to the preceding consolidation days, indicating selling pressure is dominant. There is a lack of significant volume spikes on up days, suggesting weak buying interest.

5. Estimated Chip Distribution Analysis: (Note: This is a statistical estimate based on historical OHLC and turnover behavior, not exact exchange-level holding data.)

• Average Cost: $25.80
• Current Price vs. Avg Cost: The current price ($25.34) is below the estimated average cost of $25.80.
• Profit Ratio: Only 3.27% of estimated holders are in profit. This creates a “floating loss” scenario for the majority, which can act as an overhead supply if the price attempts to rally, as many holders may look to sell at breakeven.
• Cost Concentration: The 70% cost range is tight at [$25.45, $26.15] (1.34% concentration), and the 90% range is [$25.35, $26.39] (2.01% concentration). This high concentration around the current price indicates a lack of clear cost-based support or resistance over a wide range, making the stock susceptible to sharp moves based on news or sentiment. The price is currently at the lower edge of this concentrated zone.

💭 Investment Recommendations & Risk Warnings

Synthesis of Technical Evidence: The technical picture for Pfizer, Inc. (PFE) is bearish in the short to medium term. The stock is in a clear downtrend, trading below all major moving averages, with momentum indicators (MACD) confirming the bearish trend. However, multiple oscillators (RSI, Williams %R, CCI, KDJ’s J value) are flashing extreme oversold signals. This creates a conflict between trend (down) and momentum (oversold).

Investment Recommendation: HOLD (for existing investors) / AVOID NEW BUYS (for new investors).

Rationale:

1. For Existing Holders (HOLD): Selling at these deeply oversold levels carries the risk of a “sell-the-bottom” scenario. The multitude of oversold indicators suggests a high probability of a technical bounce or consolidation in the near term. It would be prudent to wait for such a bounce to assess strength before considering exit strategies. A stop-loss could be placed just below the key support of $25.15 (lower Bollinger Band).
2. For Potential Buyers (AVOID): The adage “never try to catch a falling knife” applies here. While the stock is oversold, the primary trend is decisively down. There is no confirmed reversal pattern or bullish signal (e.g., MACD bullish crossover, close above a key moving average). The estimated chip distribution shows most holders are at a loss, creating potential selling pressure on any rally. No long positions should be initiated until the trend shows concrete signs of reversal.

Key Price Levels to Watch:

• Bullish Scenario Trigger: A daily close above the 10-day MA ($25.85) with strong volume could signal the start of a short-term recovery. A stronger signal would be a reclaim of the 60-day MA ($26.71).
• Bearish Scenario Trigger: A sustained daily close below $25.15 (lower Bollinger Band) could lead to an acceleration of the downtrend, with the next target near $24.50.

Risk Warnings:

1. Trend Risk: The dominant trend is down. Counter-trend trades (buying the dip) are high-risk without clear reversal signals.
2. Market Risk: As a large-cap pharmaceutical stock, PFE can be influenced by broader market sentiment, sector rotation, and macroeconomic factors like interest rates.
3. Fundamental Catalysts: Technical analysis exists in a vacuum without considering fundamentals. Company-specific news (drug trial results, regulatory decisions, earnings reports) can instantly override all technical patterns.
4. Chip Distribution Limitation: The provided chip analysis is an estimate with inherent limitations. It should be used to gauge general market cost structure, not as a precise trading tool.

Conclusion: Pfizer, Inc. (PFE) is technically weak but oversold. The prudent course of action is to wait for either a confirmed trend reversal signal or for the oversold condition to resolve through a consolidation or bounce. Aggressive traders might consider a very small, tactical long position only if the price shows strong rejection at the $25.15-$25.25 support zone with a bullish candlestick pattern, but this carries significant risk. Conservative investors should remain on the sidelines. ✅ Analysis Complete